NeuroSigma Expands Payment Options for the Monarch eTNS® System
Families prescribed Monarch can now pay with digital wallets or third-party installment plans at checkout
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) — NeuroSigma, Inc. today announced expanded payment options for patients prescribed the Monarch eTNS® System, the first non-drug treatment for pediatric ADHD cleared by the U.S. Food and Drug Administration.
Patients receiving a Monarch eTNS prescription can now choose from a wider range of payment methods at checkout, including digital wallets and buy now, pay later (BNPL) installment payment plans offered by third-party providers. Availability and eligibility for each method are determined by the provider at the time of purchase.
“We are delighted to offer expanded payment methods and installment plans to our patients. Price shouldn’t prevent a prescription at the checkout page,” said Colin Kealey, M.D., President and Chief Executive Officer of NeuroSigma. “Giving families more ways to pay is a practical benefit that removes friction. We are grateful to our financing partners and our dedicated pharmacy for working with us to achieve this milestone, which will put the Monarch eTNS System within reach of more families.”
The Monarch eTNS System is available by prescription only. Prescriptions are dispensed by Transition Pharmacy, and patients complete payment through a secure checkout link. Payment options shown at checkout vary by order and are subject to approval by the applicable third-party provider. NeuroSigma does not extend credit, set terms, or determine eligibility for any installment payment option.
About the Monarch eTNS System
The Monarch eTNS System is an FDA-cleared medical device that delivers external trigeminal nerve stimulation (eTNS) during sleep. It is cleared as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD medication. The device is worn overnight, with a small adhesive patch placed on the forehead connected to a handheld stimulator.
Important Safety Information
The Monarch eTNS System is available by prescription only. It is indicated for the treatment of pediatric ADHD as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medication and is intended for home use during sleep under the supervision of a caregiver. Monarch should not be used by patients with an implanted cardiac or neurostimulation system or an implanted metallic or electronic device in the head. Do not apply the device to the neck or chest, do not use it in the bath or shower, and do not use it in the presence of electrical monitoring equipment such as cardiac monitors. Apply the patch only to healthy, clean, intact skin. The most commonly reported side effects are drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue. Talk with your child’s clinician about whether Monarch is right for your child.
For complete safety information, see the Instructions for Use.
About NeuroSigma
NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients’ lives. The company’s lead product is the Monarch eTNS System, the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy, and the FDA has granted the Monarch eTNS System Breakthrough Device Designation in drug-resistant epilepsy. These pipeline indications are investigational and are not cleared by the FDA.
For more information about NeuroSigma, please visit www.neurosigma.com. For more information on the Monarch eTNS System, please visit www.monarch-etns.com.
Media Contact
Colin Kealey, M.D.
President and Chief Executive Officer, NeuroSigma, Inc.
ckealey@neurosigma.com
